The extracellular, matrix-modifying enzyme lysyl oxidase (LOX) has recently been linked to colorectal cancer (CRC) progression, in particular to the stages of invasion and metastasis. In this report, we use cell lines expressing a catalytically inactive mutant form of LOX to show that catalytic activity is required for LOX-mediated effects on proliferation and invasion in both in vitro and in vivo models of CRC. Furthermore, we use rheology to measure the relative stiffness of modified collagen matrices and subcutaneous tumors, and show that LOX-induced collagen cross-linking results in stiffening of the matrix both in vitro and in vivo. We observe a strong association between matrix stiffness and activation of the FAK (focal adhesion kinase)/SRC-signaling pathway, with a stiffer environment resulting in increased FAK/SRC phosphorylation and a more proliferative and invasive phenotype. We are the first to show a direct relationship between LOX enzymatic activity and tissue stiffness, and to demonstrate a role for stiffness in driving CRC progression. Our findings provide significant evidence to suggest that therapeutic inhibition of LOX activity may provide a novel effective treatment option for patients with metastatic CRC.
INTRODUCTION
Cancer progression involves complex, dynamic interactions between tumor cells and components of the surrounding extracellular matrix (ECM). The biomechanical and biochemical properties of the ECM are fundamental to the efficiency of invasion and metastasis. 1 In particular, the stiffness or elasticity of the cellular environment has been shown to have a critical role in cancer progression. 2 Tumor cells have the potential to modify their environment in a number of ways. A notable example is the secretion of lysyl oxidase (LOX), which catalyzes the covalent cross-linking of collagens and elastin in the ECM, thereby increasing tissue stiffness and enhancing tumor progression. 3 Elevated LOX expression has been associated with invasion and metastasis in a number of solid tumors, notably breast, 4 colorectal 5 and head and neck. 6 Inhibition of LOX has shown considerable promise in a number of preclinical models and has subsequently become a novel target for therapeutic intervention.
A central component of the signaling cascades responsible for transducing extracellular mechanical force to changes in gene expression within the cell is focal adhesion kinase (FAK). 7 As such it has been studied intensively in the context of cancer, and has emerged as a notable target for drug development. 7 FAK activation is closely associated with phosphorylation of SRC tyrosine kinase, with signaling through these kinases being frequently upregulated during the progression of cancer. 8 SRC has been shown to be critical for LOX-mediated invasion of colorectal cancer (CRC) cells, 5 and both SRC and FAK are implicated in LOX-mediated invasion of breast cancer cells. 4, 9 Early studies into the role of LOX in CRC gave conflicting results. Csiszar et al. 10 showed decreased LOX mRNA expression levels in CRC patients with non-metastatic disease, suggesting a role for LOX as a tumor suppressor. However, a more recent study showed that LOX mRNA expression was associated with a diffuse cytoplasmic expression of CEA (carcinoembryonic antigen) in CRC patients suggesting LOX was associated with increased invasive potential. 11 Our previous study confirmed a role for LOX in CRC cancer progression. 12 Here, we now report that LOX catalytic activity significantly increases tissue stiffness in a CRC model, and use clinically relevant inhibitors to show that this contributes to tumor proliferation and metastasis in a FAK/SRCdependent manner.
RESULTS AND DISCUSSION
LOX activity promotes proliferation and increases stiffness of subcutaneous tumors To determine the effect of LOX activity on tumor stiffness, the CRC cell lines SW480, HT29 and LS174T were stably transfected with an empty vector control, full-length LOX, or a catalytically inactive full-length LOX (containing the mutation K320A) as previously described. 5 Overexpression of mutant LOX resulted in an increase in protein expression (Supplementary Figure 1a) but no change in amine oxidase activity (Supplementary Figure 1b) . These cell lines were implanted into nude mice and allowed to grow as subcutaneous tumors. Consistent with our previous findings expressing catalytically inactive LOX, the tumors grew at a similar rate to (in the cases of HT29 and LS174T) or even significantly slower than the control tumors (in the case of SW480). These data suggest that the catalytic activity of LOX is essential for LOXmediated promotion of tumor growth.
The stiffness of the tumors was measured using an ARG2 controlled strain rotational rheometer (TA Instruments, Crawley, UK), and the results showed that SW480 tumors overexpressing full-length active LOX were significantly stiffer than the control tumors or those expressing catalytically inactive mutant LOX (Figure 1b) . The same trend was observed in the HT29 and LS174T tumors (Supplementary Figure 1d) . The collagen content of the tumors was measured using the Sircol assay (BioColor Ltd, Carrickfergus, UK), and no significant difference in fibrillar collagen content was observed (Figure 1c) , suggesting that the changes in stiffness can be attributed to a modification of existing collagen rather than an increase in collagen production.
LOX-mediated collagen modification increases phosphorylation of FAK at tyrosine 397 We have previously shown that active LOX increases SRC(Tyr418) phosphorylation and promotes 3D proliferation in collagen in vitro. 5 Here, we show that LOX catalytic activity in the SW480 cell line promotes FAK(Tyr397) phosphorylation in vitro (Figure 2a) , and confirm these findings in the HT29 and LS174T cell lines (Supplementary Figure 2a) . To confirm that these effects are due to LOX-mediated modification and in particular stiffening of the surrounding collagen matrix, we pre-treated collagen matrices with either recombinant human LOX (huLOX) or ribose, which is also known to cross-link collagen.
14 Both huLOX and ribose treatment significantly increased the stiffness of collagen matrices, as measured by rheology ( Figure 2b ). SW480, HT29 or LS174T cells were seeded onto the pre-modified matrices for 16 h, and then analyzed for FAK and SRC phosphorylation by immunoblot. The results show that seeding cells onto a pre-modified stiffer collagen surface is sufficient to activate the FAK-signaling pathway ( Figure 2c and Supplementary Figure 2b) . This recapitulates the phenotype of the LOX-overexpressing cells, and confirms that LOX-mediated collagen cross-linking and subsequent stiffening is responsible for the increase in intracellular FAK and SRC phosphorylation.
LOX activity and FAK/SRC activation are required for LOX-mediated promotion of proliferation in vitro We have previously shown that overexpression of LOX promotes 3D proliferation in collagen in vitro via SRC phosphorylation. 5 Here, we sought to determine whether LOX catalytic activity is essential for these changes in 3D cultures, and whether FAK activation is also required. Cells were seeded into collagen and allowed to proliferate for 10 days before digestion of the collagen matrix and quantification of total viable cells. As previously reported, 5 LOX overexpression promotes growth in collagen, and this can be Figure 2c) , suggesting that LOX enzymatic activity is essential to confer an increase in proliferation.
LOX activity promotes activation of FAK signaling in vivo To confirm that LOX activity increases FAK and SRC phosphorylation in vivo, the cell lines were implanted as subcutaneous tumors in nude mice (See Figure 1) . Immunohistochemical staining was used to visualize LOX (Figure 3a) , FAK (Tyr397; Figure 3b ) and SRC (Tyr418; Figure 3c ) in SW480 tumor sections, and as reported previously, 5 overexpression of LOX resulted in an increase in both FAK and SRC phosphorylation. However, although overexpression of the catalytically inactive LOX ('mut LOX') was stable in vivo (Figure 3a) , it failed to induce FAK or SRC phosphorylation ( Figures  3b and c) , confirming that the enzymatic activity of LOX is responsible for the increase in FAK signaling in CRC tumors in vivo. Furthermore, consistent results were observed in both the HT29 and LS174T subcutaneous tumor models ( Supplementary  Figures 3a-c) suggesting that upregulation of FAK and SRC phosphorylation, as mediated by LOX activity, may be a general mechanism in CRC. Figure 2 . LOX-mediated matrix stiffening increases FAK signaling in vitro. (a) Representative immunoblot analysis of phosphorylated FAK(Tyr397) ('FAK-P') levels in SW480 cells stably overexpressing LOX (' þ LOX') or LTQ mutant LOX (' þ mut LOX'). Cells were cultured on 2.5 mg/ml collagen-coated wells for 16 h before treating with NP40 lysis buffer and analysis by immunoblotting as previously described. 5 b actin was used as the loading control. (b) Relative stiffness of LOX-or ribose-modified collagen gels as measured by rheology. Wells were coated with 1.5 mg/ml collagen and allowed to set at room temperature (RT) for 30 min followed by 37 1C for 2 h before adding PBS only ('Col I'), or PBS containing 60 mM ribose ('Col I þ Rib'; Sigma-Aldrich, Dorset, UK) or 150 ng/ml human recombinant LOX ('Col I þ LOX'; OriGene, Rockville, MD, USA) and incubating at 37 1C for 5 days. Stiffness was subsequently measured under the following conditions; briefly, 25 mm diameter, 1-mm thick collagen hydrogels were measured over a range of 0.5-1.25% strain at a fixed angular frequency of 0.5 rad/s and temperature of 21 1C on an ARG2 controlled strain rotational rheometer (TA Instruments). The samples were found to be only minimally frequency dependent within the range of testing and showed linear viscoelastic response within the strain range evaluated. Data are representative of two independent experiments. Bars represent mean ± s.e.m., *Po0.05 and **Po0.01 using the two-sided Student's t-test. (c) Representative immunoblot analysis of phosphorylated FAK(Tyr397) ('FAK-P') and phosphorylated SRC(Tyr418) ('SRC-P') levels in SW480 cells cultured on huLOX-or ribose-modified 1.5 mg/ml collagen matrix. After 5 days modification as described above, the wells were then washed with PBS for 1 h and SW480 cells were added for 16 h before treating with NP40 lysis buffer and analysis by immunoblotting as previously described. 5 b actin was used as the loading control. (d) Effect of FAK and SRC inhibition on growth of SW480 cells in collagen. Cells were seeded into collagen gels as previously described 5 and incubated at 37 1C for 10 days before digesting the collagen and counting viable cells. Media was supplemented with 1 mM dasatinib (LC Laboratories, Woburn, MA, USA), 5 mM FAK inhibitor 14 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or vehicle control ('DMSO'). Bars represent mean ± s.e.m., **Po0.01 and ***Po0.001 using the two-sided Student's t-test. kDa, kilodalton.
LOX activity promotes invasion and metastasis, via b1-integrin activation and FAK/SRC signaling We have previously reported that LOX overexpression can promote invasion through collagen, and LOX knockdown can suppress invasion through collagen. 5 Here, we use SW480 cells overexpressing catalytically inactive mutant LOX to determine whether LOX catalytic activity is required for enhancing invasion. Consistently, we found that overexpression of full-length LOX promoted invasion of the cells through collagen, but overexpression of inactive LOX was not able to promote invasion (Figure 4a) . Notably, overexpression of active or inactive LOX did not affect migration of cells through a transwell membrane (Supplementary Figures 4a and 4b) . Furthermore, addition of dasatinib and FAK inhibitor 14 significantly reduced the invasion of LOX-overexpressing cells through collagen, suggesting that FAK/SRC signaling is required for LOX-mediated invasion through collagen (Figure 4a ). It has previously been reported that FAK and SRC are activated by collagen via b1-integrin signaling. 16 Therefore, we carried out invasion assays in the presence of a b1-integrin blocking antibody and show that inhibtion of the b1-integrin subunit results in a significant decrease in invasion of high LOX-expressing cells (Supplementary Figure 4c ). This is consistent with reports that LOXmediated invasion in a breast cancer model requires b1-integrin activity. 3 To confirm that it is LOX-mediated cross-linking, which promotes invasion through collagen, we coated transwell inserts with a thin layer of collagen, then pre-modified the matrix with 'huLOX' or ribose for 5 days before seeding cells. We found that cells were more able to invade through collagen that had been pre-modified (Figures 4b and c) , suggesting that cross-linking of collagen promotes cell invasion.
To investigate whether LOX catalytic activity is required for promoting metastasis in vivo, we implanted the luciferaseexpressing SW480 cell lines with manipulated LOX levels into the spleen of nude mice and monitored the dissemination of tumor cells. As previously reported, we found that SW480 cells were poorly metastatic, and overexpression of active LOX resulted in an increased propensity for cells to metastasize. 5 However,
where the implanted cells were overexpressing the catalytically inactive form of LOX, the cells were not able to metastasize (Figures 4d and e) , suggesting that LOX-mediated cross-linking events are required for efficient metastasis to occur in this model. This is of significance as it confirms that therapeutic inhibition of LOX activity may provide an effective treatment for patients with metastatic CRC. Alternatively, targeting the mechano-sensing ability of tumor cells could prevent them from responding in a pro-metastatic manner to changes in tissue stiffness. It is well established that mechanical stiffness of tumor ECM is a property fundamental to tumor progression. 2 Furthermore, the analysis of tissue stiffness is already utilized in the clinic as a means to detect and monitor tumor growth. 17 Tumors are known to increase and respond to changes in ECM stiffness via integrin activation and subsequent phosphorylation of FAK, resulting in Rho/ROCK activation and remodeling of the actin cytoskeleton. 18 In addition, LOX-mediated cross-linking events have previously been proposed to promote breast cancer malignant progression upstream of this mechanism by increasing ECM stiffness. 3 Here, we use in vitro and in vivo models of CRC to show that LOXcatalyzed cross-linking of collagen is sufficient to increase tumor stiffness and induce FAK signaling.
Our findings support existing reports that elevated tumor stiffness increases malignancy 2, 3, 19 and that LOX activity acts to drive metastasis at the extracellular level. We also provide data to support a key role for LOX catalytic activity in promoting stiffnessinduced proliferation and invasion. These data have important clinical implications for the development of therapeutic LOX inhibitors, highlighting that the effective inhibition of LOX catalytic activity is absolutely crucial to abrogate LOX-mediated ECM-driven proliferation and invasion.
In summary, we show that LOX-mediated collagen cross-linking results in increased tissue stiffness and activation of the FAK/SRC signaling in in vitro and in vivo models of CRC. We further show that as a consequence, cells expressing high levels of enzymatically active LOX protein have an increased capacity to proliferate, invade and metastasize. This suggests that inhibition of LOX catalytic activity may provide a novel effective treatment option for patients with CRC to prevent metastatic progression. Invasion assays through collagen were carried out as previously described. 5 The collagen matrix was supplemented with 1 mM dasatinib, 5 mM FAK inhibitor 14 or vehicle control. (b) Effect of LOX-or ribose-mediated collagen modification on invasion of SW480 cells through collagen matrix. Transwell inserts of 8 mm pore size (BD Bioscience, Oxford, UK) were coated with a thin layer of 1.8 mg/ml collagen (BD Bioscience) and allowed to set at RT for 30 min, then 2 h at 37 1C before adding PBS containing 60 mM ribose ('Ribose treated') or 150 ng/ml huLOX ('huLOX treated') and incubating at 37 1C for 5 days. The PBS was then removed and the matrix was washed with fresh PBS for 1 h. Cells were serum starved for 24 h before harvesting in serum free Dulbecco's modified Eagle medium (DMEM; Invitrogen) and seeding 2 Â 10 5 onto the collagen layer. DMEM containing 10% fetal bovine serum was used as a chemoattractant. Plates were incubated for 24 h at 37 1C before fixing in methanol for 5 min at RT and staining in 1% toluidine blue (Sigma-Aldrich) for 15 min at RT. Inserts were washed in water and the number of invaded cells per field of view was analyzed. Four fields of view per well and two wells per condition were counted. (c) Representative images of invaded cells after fixing and staining with toluidine blue. Images were taken using an Eclipse TS100 inverted light microscope (Nikon UK Ltd, Kingston upon Thames, UK). (d) Analysis of metastatic burden in an intrasplenic model. Luciferase-expressing SW480 cells (2 Â 10 6 ) were surgically implanted into the spleen of nude mice (n ¼ 6 for each condition) and metastatic burden was measured as total normalized luminescent signal from metastatic organs (liver, colon and stomach) at the experimental endpoint (4-5 weeks from surgery) as previously described. 5 Data are representative of two independent experiments. Bars represent mean±s.e.m. (e) Representative images of mice surgically implanted with luciferaseexpressing SW480 cells into the spleen, illustrating a high metastatic burden in mice implanted with cells expressing high levels of wild-type LOX ('SW480 þ LOX'). Bars in (a) and (b) represent mean ± s.e.m., *Po0.05, **Po0.01 and ***Po0.001 using the two-sided Student's t test.
